MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
-
May 7, 2026
-
4 min
Clinical Report: MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM
Overview
MimiVax and Roswell Park have launched a phase 2 trial evaluating SurVaxM combined with temozolomide in patients with progressing metastatic neuroendocrine tumors (NETs). This trial aims to assess the safety and efficacy of this combination therapy, building on promising phase 1 results.
Background
Neuroendocrine tumors (NETs) are rare malignancies that have seen a rise in incidence, with approximately 28,000 new cases diagnosed annually in the U.S. Metastatic NETs have a poor prognosis and limited treatment options following first-line therapies, such as somatostatin analogs and chemotherapy. The development of new immunotherapeutic strategies, such as SurVaxM, is critical for improving outcomes in this patient population.
Data Highlights
Key findings from the phase 1 trial indicate that SurVaxM was well tolerated and generated measurable immune responses in NET patients.Key Findings
- SurVaxM is a peptide vaccine targeting the survivin protein, which is expressed in about 52% of NET specimens, correlating with aggressive tumor behavior.
- The phase 1 trial demonstrated that SurVaxM was well tolerated and generated measurable immune responses in NET patients.
- The ongoing phase 2 trial compares the combination of SurVaxM and temozolomide against temozolomide alone.
- SurVaxM may block the growth of new tumor cells, providing a potential new treatment option for NET patients.
- Immunotherapy has shown limited efficacy in NETs, highlighting the need for innovative treatment approaches.
Clinical Implications
The initiation of this phase 2 trial may offer new therapeutic options for patients with metastatic NETs, particularly those who have limited choices after first-line treatments. The results could inform future treatment protocols, potentially leading to improved patient care in this challenging clinical area.
Conclusion
The phase 2 trial of SurVaxM represents a significant step forward in the search for effective treatments for metastatic neuroendocrine tumors. Continued research in this area is essential for improving patient outcomes.
References
- Roswell Park Comprehensive Cancer Center, Source, 2023 -- Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy
- Roswell Park Comprehensive Cancer Center, Source, 2023 -- Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM
- The ASCO Post, Source, 2017 -- Clinical Trials Actively Recruiting Patients With Gynecologic Cancers
- European Neuroendocrine Tumor Society (ENETS), Source, 2024 -- Guidance paper for the management of well-differentiated small intestine neuroendocrine tumours
- The ASCO Post — Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
- European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours - PubMed
- (PDF) Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Based on findings from:
MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
Roswell Park Comprehensive Cancer Center, 2026.
https://physicianresources.roswellpark.org/news/mimivax-and-roswell-park-open-phase-2-trial-of-survaxm-for-patients-with-metastatic-neuroendocrine-tumors
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
